No. The FDA got burned on MDMA’s weak trial data, and no psychedelic has a clean enough approval package lined up to cross the finish line this year.
Agreed. Even the furthest-along programs like COMP360 are still mid-Phase 3, and the FDA's post-Lykos caution means they'll want bulletproof blinding data nobody has yet.
